Stoke Therapeutics Financials
| STOK Stock | USD 11.27 0.04 0.35% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.64 | 6.9872 |
|
|
The essential information of the day-to-day investment outlook for Stoke Therapeutics includes many different criteria found on its balance sheet. An individual investor should monitor Stoke Therapeutics' cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Stoke Therapeutics.
Net Income |
|
Stoke | Select Account or Indicator |
Understanding current and past Stoke Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Stoke Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Stoke Therapeutics' assets may result in an increase in income on the income statement.
Stoke Therapeutics Stock Summary
Stoke Therapeutics competes with ZyVersa Therapeutics, Sonnet Biotherapeutics, Zura Bio, Phio Pharmaceuticals, and Transcode Therapeutics. Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases in the United States. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts. Stoke Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 102 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US86150R1077 |
| CUSIP | 86150R107 |
| Location | Massachusetts; U.S.A |
| Business Address | 45 Wiggins Avenue, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.stoketherapeutics.com |
| Phone | 781 430 8200 |
| Currency | USD - US Dollar |
Stoke Therapeutics Key Financial Ratios
| Return On Equity | -0.52 | ||||
| Operating Margin | (6.13) % | ||||
| Price To Sales | 35.78 X | ||||
| Revenue | 8.78 M | ||||
| Gross Profit | 12.4 M |
Stoke Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 228.8M | 297.9M | 238.9M | 256.1M | 228.3M | 213.7M | |
| Other Current Liab | 3.4M | 8.9M | 13.2M | 13.4M | 11.8M | 8.7M | |
| Other Liab | 221K | 342K | 3.9M | 37.1M | 42.7M | 44.8M | |
| Net Tangible Assets | 224.4M | 286.1M | 217.8M | 184.8M | 212.6M | 186.4M | |
| Net Debt | (222.5M) | (287.2M) | (143.4M) | (111.2M) | (189.4M) | (198.8M) | |
| Retained Earnings | (58.0M) | (110.3M) | (196.1M) | (297.2M) | (401.8M) | (381.8M) | |
| Accounts Payable | 751K | 1.5M | 2.4M | 766K | 1.7M | 1.3M | |
| Cash | 222.5M | 287.3M | 144.9M | 113.6M | 191.4M | 167.7M | |
| Other Assets | 205K | 1.3M | 248.5M | 569K | 654.4K | 621.6K | |
| Capital Surpluse | 282.5M | 396.4M | 414.0M | 483.2M | 555.6M | 315.1M | |
| Other Current Assets | 3.3M | 6.6M | 9.3M | 13.9M | 13.9M | 7.5M | |
| Total Liab | 4.3M | 11.8M | 21.1M | 71.2M | 68.8M | 72.2M | |
| Net Invested Capital | 224.4M | 286.1M | 217.8M | 184.8M | 159.6M | 184.9M | |
| Total Current Assets | 226.0M | 293.9M | 229.2M | 244.1M | 215.3M | 206.9M | |
| Net Working Capital | 221.9M | 282.5M | 212.1M | 212.7M | 184.5M | 191.0M | |
| Net Receivables | 281K | 6K | 132K | 588K | 64K | 60.8K |
Stoke Therapeutics Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Net Interest Income | 3.4M | 744K | 120K | 3.1M | 8.8M | 9.2M | |
| Interest Income | 270K | 3.4M | 744K | 120K | 138K | 131.1K | |
| Gross Profit | (450K) | (1.9M) | (2.2M) | 12.4M | 4.1M | 4.3M | |
| Operating Income | (35.7M) | (53.0M) | (86.1M) | (104.4M) | (114.8M) | (109.0M) | |
| Ebit | (35.7M) | (53.0M) | (86.1M) | (104.4M) | (114.8M) | (109.0M) | |
| Research Development | 23.8M | 32.2M | 54.2M | 77.8M | 82.2M | 44.3M | |
| Ebitda | (35.2M) | (52.2M) | (85.1M) | (102.8M) | (112.3M) | (106.7M) | |
| Cost Of Revenue | 450K | 1.9M | 2.2M | 3.5M | 4.7M | 5.0M | |
| Income Before Tax | (32.3M) | (52.2M) | (85.8M) | (101.1M) | (104.7M) | (99.5M) | |
| Net Income | (28.5M) | (50.6M) | (84.7M) | (93.1M) | (104.7M) | (99.5M) | |
| Income Tax Expense | (3.8M) | (1.6M) | (1.1M) | (8.0M) | 4.6M | 4.8M |
Stoke Therapeutics Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | (1.6M) | (1.1M) | (75.2M) | (41.9M) | 113.7M | 119.3M | |
| Change In Cash | 117.1M | 64.8M | (142.0M) | (31.3M) | 77.9M | 81.8M | |
| Free Cash Flow | (32.7M) | (43.3M) | (68.1M) | (35.8M) | (82.7M) | (78.5M) | |
| Depreciation | 450K | 888K | 974K | 1.5M | 2.5M | 2.6M | |
| Other Non Cash Items | 3K | 1.0M | 1.3M | 1.8M | 1.9M | 2.0M | |
| Capital Expenditures | 1.6M | 1.1M | 1.2M | 4.0M | 1.6M | 1.7M | |
| Net Income | (32.3M) | (52.2M) | (85.8M) | (101.1M) | (104.7M) | (99.5M) | |
| End Period Cash Flow | 222.7M | 287.5M | 145.5M | 114.1M | 192.0M | 168.0M | |
| Change To Netincome | 1.9M | 5.8M | 16.5M | 22.9M | 26.3M | 27.6M |
Stoke Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Stoke Therapeutics's current stock value. Our valuation model uses many indicators to compare Stoke Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Stoke Therapeutics competition to find correlations between indicators driving Stoke Therapeutics's intrinsic value. More Info.Stoke Therapeutics is rated second in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Stoke Therapeutics' Return On Equity is quite stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Stoke Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Stoke Therapeutics Systematic Risk
Stoke Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Stoke Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Beta measures systematic risk based on how returns on Stoke Therapeutics correlated with the market. If Beta is less than 0 Stoke Therapeutics generally moves in the opposite direction as compared to the market. If Stoke Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Stoke Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Stoke Therapeutics is generally in the same direction as the market. If Beta > 1 Stoke Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Stoke Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Stoke Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Stoke Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Stoke Therapeutics November 21, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Stoke Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Stoke Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Stoke Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Stoke Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Stoke Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.11) | |||
| Maximum Drawdown | 21.35 | |||
| Value At Risk | (7.09) | |||
| Potential Upside | 4.68 |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Stoke Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Stoke Stock please use our How to buy in Stoke Stock guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Stoke Therapeutics. If investors know Stoke will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Stoke Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.08) | Revenue Per Share 0.328 | Quarterly Revenue Growth 0.479 | Return On Assets (0.28) | Return On Equity (0.52) |
The market value of Stoke Therapeutics is measured differently than its book value, which is the value of Stoke that is recorded on the company's balance sheet. Investors also form their own opinion of Stoke Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Stoke Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Stoke Therapeutics' market value can be influenced by many factors that don't directly affect Stoke Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Stoke Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Stoke Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Stoke Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.